New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
11:28 EDTCERS, AVNR, CLH, LITB, ITBHigh option volume stocks: CERS AVNR CLH LITB ITB
News For CERS;AVNR;CLH;LITB;ITB From The Last 14 Days
Check below for free stories on CERS;AVNR;CLH;LITB;ITB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
09:02 EDTAVNRConcert Pharmaceuticals achieves $2M milestone for AVP-786
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. The agreement provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan compounds. The licensed compounds are believed to have potential for the treatment of neurological and psychiatric disorders. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the second development milestone Concert has earned under the agreement.
09:02 EDTAVNRAvanir initiates AVP-786 phase II study
Subscribe for More Information
August 22, 2014
12:39 EDTAVNRThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
07:29 EDTCLHClean Harbors coverage resumed with a Buy at Stifel
Subscribe for More Information
August 20, 2014
06:11 EDTLITBLightInTheBox sees Q3 revenue $92M-$94M, consensus $84.95M
Subscribe for More Information
06:11 EDTLITBLightInTheBox reports Q2 EPS (11c), consensus (11c)
Reports Q2 revenue $89.8M, consensus $84.8M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use